FLEXION THERAPEUTICS, INC.

(FLXN)
Delayed Nasdaq  -  11/18 04:00:00 pm EST
9.120 USD   -0.22%
03/28Renovacor Names New CFO
MT
2021Pacira BioSciences Logs Higher Exparel, Iovera Sales in November
MT
2021NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
SummaryQuotesChartsNewsRatingsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Flexion Therapeutics, Inc.(NasdaqGM:FLXN) dropped from NASDAQ Composite Index

11/19/2021 | 12:00am EDT

Flexion Therapeutics, Inc. has been removed from NASDAQ Composite Index (^COMP) .


© S&P Capital IQ 2021
All news about FLEXION THERAPEUTICS, INC.
03/28Renovacor Names New CFO
MT
2021Pacira BioSciences Logs Higher Exparel, Iovera Sales in November
MT
2021NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
2021Northland Securities Downgrades Flexion Therapeutics to Market Perform From Outperform,..
MT
2021FLEXION THERAPEUTICS INC : Entry into a Material Definitive Agreement, Termination of a Ma..
AQ
2021FLEXION THERAPEUTICS, INC.(NASDAQGM : FLXN) dropped from NASDAQ Composite Index
CI
2021FLEXION THERAPEUTICS, INC.(NASDAQGM : FLXN) dropped from S&P Global BMI Index
CI
2021FLEXION THERAPEUTICS, INC.(NASDAQGM : FLXN) dropped from S&P TMI Index
CI
2021FLEXION THERAPEUTICS, INC.(NASDAQGM : FLXN) dropped from NASDAQ Biotechnology Index
CI
2021FLEXION THERAPEUTICS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
More news
Analyst Recommendations on FLEXION THERAPEUTICS, INC.
More recommendations
Chart FLEXION THERAPEUTICS, INC.
Duration : Period :
Flexion Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Carolyn Beaty Scimemi Chief Compliance Officer & Head-Legal Affairs
Scott A. Young VP-Corporate Communications & Investor Relations
Sector and Competitors
1st jan.Capi. (M$)
FLEXION THERAPEUTICS, INC.0.00%459
GILEAD SCIENCES, INC.-12.93%79 298
REGENERON PHARMACEUTICALS, INC.4.38%71 026
VERTEX PHARMACEUTICALS14.91%64 540
WUXI APPTEC CO., LTD.-18.77%41 409
BIONTECH SE-39.08%38 169